Camena Bioscience
Steve Harvey began their work experience in 2006 as a Post-doc at the University of Cambridge. Steve then went on to become a Scientist at the Wellcome Trust Sanger Institute from 2010 to 2015. In 2016, Harvey became the CEO of Camena Bioscience, a company that develops DNA synthesis technology to provide scientists with access to long and complex gene sequences.
Steve Harvey completed their Bachelor of Science (BSc) degree in Human genetics from the University of Nottingham from 1999 to 2002. Steve then pursued a Doctor of Philosophy (PhD) degree in Developmental Biology from the MRC National Institute for Medical Research from 2002 to 2006.
This person is not in any teams
Camena Bioscience
Camena Bioscience is a synthetic biology company that develops tools to engineer new synthetic biology applications. It has engineered new nucleic acid synthesis technology which improves the quality and speed of synthesis. Its multi-enzymatic technology takes one approach to DNA, RNA, and XNA synthesis, offering increased accuracy over existingPhosphoramidite synthesis technology.Camena Bioscience was founded in 2016 and is headquartered in Cambridge.